Is BetterLife Pharma Inc. (BETRF) a Buy, Sell, or Hold?
OTC : BETRF
BetterLife Pharma Inc.
$0.161 USD
$0.0 (-1.8%)
- Volume
- 10.3K
- Average Volume
- 89.83K
- Market Capitalization
- $26.06M
- P/E Ratio
- -17.20
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.17
- Year Low
- $0.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.04
| Source | Headline |
|---|---|
|
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional future indications Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache disorders as its lead indications. The strategic focus concentrates BETR-001's development on one of the largest, most disabling and most underserved areas of neurology, and does so through a serotonin-receptor mechanism of action that is already clinically validated and approved by the U.S. Food and Drug Administration (FDA) in multiple marketed migraine therapies. newsfilecorp.com - 2026-07-13 08:00:00 |
|
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. newsfilecorp.com - 2026-07-06 08:00:00 |
|
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. newsfilecorp.com - 2026-06-25 08:00:00 |
|
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced feeds.newsfilecorp.com - 2026-06-22 08:00:00 |
|
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the feeds.newsfilecorp.com - 2026-05-13 08:00:00 |
